[1]
|
Markman, J.L., Rekechenetskiy, A., Holler, E., et al. (2018) Nanomedicine Therapeutic Approaches to Overcome Cancer Drug Resistance. Advanced Drug Delivery Reviews, 65, 1866-879. https://doi.org/10.1016/j.addr.2013.09.019
|
[2]
|
Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancer in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
|
[3]
|
Zhao, D., Chen, Q., Song, H., et al. (2018) Theranostic Micelles Combined with Multiple Strategies to Effectively Overcome Multidrug Resistance. Nanomedicine, 13, 1517-1533. https://doi.org/10.2217/nnm-2017-0393
|
[4]
|
Wu, Q., Yang, Z., Nie, Y., Shi, Y., et al. (2014) Multi-Drug Re-sistance in Cancer Chemotherapeutics: Mechanisms and Lab Approaches. Cancer Letters, 347, 159-166. https://doi.org/10.1016/j.canlet.2014.03.013
|
[5]
|
Kumar, P., Zhang, D.M., Degenhardt, K. and Chen, Z.S. (2012) Autophagy and Transporter Based Multi-Drug Resistance. Cells, 1, 558-575. https://doi.org/10.3390/cells1030558
|
[6]
|
Kathawala, R.J., Wang, Y.J., Ashby Jr., C.R., et al. (2014) Recent Ad-vances Regarding the Role of ABC Subfamily C Member 10 (ABCC10) in the Efflux of Antitumor Drugs. Chinese Journal of Cancer, 33, 223-230.
https://doi.org/10.5732/cjc.013.10122
|
[7]
|
Nabekura, T., Kawasaki, T., Furuta, M., et al. (2018) Effects of Natural Polyphenols on the Expression of Drug Efflux Transporter P-Glycoprotein in Human Intestinal Cells. ACS Omega, 3, 1621-1626.
https://doi.org/10.1021/acsomega.7b01679
|
[8]
|
Festa, L., Roth, L.M., Jensen, B.K., et al. (2019) Protease Inhib-itors, Saquinavir and Darunavir, Inhibit Oligodendrocyte Maturation: Implications for Lysosomal Stress. Journal of Neuroimmune Pharmacology.
https://doi.org/10.1007/s11481-019-09893-8
|
[9]
|
Anreddy, N., Gupta, P., Kathawala, R.J., et al. (2014) Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance. Molecules, 19, 13848-13877. https://doi.org/10.3390/molecules190913848
|
[10]
|
de Klerk, D.J., Honeywell, R.J., Jansen, G. and Peters, G.J. (2018) Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strat-egies to Overcome Resistance. Cancers (Basel), 10, 503.
|
[11]
|
Chun, S.Y., Kwon, Y.S., Nam, K.S. and Kim, S. (2015) Lapatinib Enhances the Cytotoxic Effects of Doxorubicin in MCF-7 Tumorspheres by Inhibiting the Drug Efflux Function of ABC Transporters. Biomedicine & Pharmacotherapy, 72, 37-43. https://doi.org/10.1016/j.biopha.2015.03.009
|
[12]
|
Zhang, G.N., Ashby, C.R., Zhang, Y.K., et al. (2015) The Re-versal of Antineoplastic Drug Resistance in Cancer Cells by β-Elemene. Chinese Journal of Cancer, 34, Article No.: 45. https://doi.org/10.1186/s40880-015-0048-0
|
[13]
|
Chen, S.-N., Chang, R., Lin, L.-T., et al. (2019) MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities. International Journal of Environmental Research & Public Health, 16, 1510.
|
[14]
|
Zheng, T., Wang, J., Chen, X., et al. (2010) Role of microRNA in Anticancer Drug Resistance. International Journal of Cancer, 126, 2-10. https://doi.org/10.1002/ijc.24782
|
[15]
|
Liao, R.R., Lin, Y.X. and Zhu, L.H. (2018) Molecular Pathways Involved in microRNA-Mediated Regulation of Multidrug Resistance. Molecular Biology Reports, 45, 2913-2923.
|
[16]
|
修一冉, 马秀梅. 肿瘤干细胞标志物研究进展[J]. 世界最新医学信息文摘, 2018, 18(A5): 75-77, 79.
|
[17]
|
王纪珍, 陈君敏, 曾志勇, 等. 自噬调节药物对多发性骨髓瘤细胞增殖、凋亡和自噬的影响[J]. 中国实验血液学杂志, 2018(3): 817-823.
|
[18]
|
徐桂芳, 张伟杰, 周志华. 肿瘤干细胞与多药耐药[J]. 国际肿瘤学杂志, 2012, 39(12): 902-904.
|
[19]
|
Vinod, B.S., Maliekal, T.T. and Anto, R.J. (2013) Phytochemicals as Chemosensitizers: From Molecular Mechanism to Clinical Significance. Antioxidants & Redox Signaling, 18, 1307-1348. https://doi.org/10.1089/ars.2012.4573
|
[20]
|
谭川, 黄杰. 肺癌患者外周血miR-214表达及对肺癌细胞凋亡和多药耐药的影响[J]. 中华实用诊断与治疗杂志, 2019(11): 1073-1077.
|
[21]
|
孙晓冉, 孙剑经, 张林西. 肿瘤多药耐药机制的研究进展[J]. 现代肿瘤医学, 2017(1): 169-171.
|
[22]
|
Wu, Z., Li, S., Tang, X., Wang, Y., et al. (2020) Copy Number Amplification of DNA Damage Repair Pathways Potentiates Therapeutic Resistance in Cancer. Theranostics, 10, 3939-3951. https://doi.org/10.7150/thno.39341
|
[23]
|
郭姗琦, 赵海丰, 张翼鷟. 恶性淋巴瘤的表观遗传调控与治疗[J]. 中华肿瘤杂志, 2014, 36(3): 161-164.
|
[24]
|
Nobili, S., Landini, I., Mazzei, T., et al. (2012) Overcoming Tumor Multidrug Resistance Using Drugs Able to Evade P-Glycoprotein or to Exploit Its Expression. Medicinal Research Reviews, 32, 1220-1262.
https://doi.org/10.1002/med.20239
|
[25]
|
Duran, G.E., Derdau, V., Weitz, D., et al. (2018) Cabazitaxel Is More Ac-tive than First-Generation Taxanes in ABCB1(+) Cell Lines Due to Its Reduced Affinity for P-Glycoprotein. Cancer Chemotherapy & Pharmacology, 81, 1095-1103.
https://doi.org/10.1007/s00280-018-3572-1
|
[26]
|
Lhommé, C., Joly, F., Walker, J.L., et al. (2008) Phase III Study of Valspodar (PSC 833) Combined with Paclitaxel and Carboplatin Compared with Paclitaxel and Carboplatin Alone in Patients with Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Peritoneal Cancer. Journal of Clinical Oncology, 26, 2674-2682.
https://doi.org/10.1200/JCO.2007.14.9807
|
[27]
|
Karbanova, S., Cerveny, L., Jiraskova, L., et al. (2019) Transport of Ribavirin across the Rat and Human Placental Barrier: Roles of Nucleoside and ATP-Binding Cassette Drug Efflux Transporters. Biochemical Pharmacology, 163, 60-70. https://doi.org/10.1016/j.bcp.2019.01.024
|
[28]
|
Cui, Q.B., Wang, J.-Q., Assaraf, Y.G., et al. (2018) Modulating ROS to Overcome Multidrug Resistance in Cancer. Drug Re-sistance Updates: Reviews &Commentaries in Antimicrobial & Anticancer Chemotherapy, 41, 1-25.
|
[29]
|
张游华, 顾轫赜, 牛天力, 等. DNA拓扑异构酶抑制剂在逆转肿瘤多药耐药性中的研究进展[J]. 现代肿瘤医学, 2016(24): 4033.
|
[30]
|
Miyahara, D., Ueda, T., Katsuda, T., et al. (2015) The Safety of Pegylated Liposomal Doxorubicin plus Irinotecan in Recurrent Ovarian Cancer Patients: A Phase I Trial. Anticancer Res, 35, 4521-4525.
|
[31]
|
Peng, X., Zhang, M.Q.Z., Conserva, F., et al. (2013) APR-246/PRIMA-1MET Inhibits Thioredoxinreductase1 and Converts the Enzyme to a Dedicated NADPH Oxidase. Cell Death & Disease, 4, e881.
https://doi.org/10.1038/cddis.2013.417
|
[32]
|
Ding, X. and Matsuo, K. (2015) Optimized Combinations of Borte-zomib, Camptothecin, and Doxorubicin Show Increased Efficacy and Reduced Toxicity in Treating Oral Cancer. An-ti-Cancer Drugs, 26, 547-554.
https://doi.org/10.1097/CAD.0000000000000222
|
[33]
|
Peleg, R., Romzova, M., Kogan-Zviagin, I., et al. (2014) Modification of Topoisomerases in Mammospheres Derived from Breast Cancer Cell Line: Clinical Implications for Combined Treatments with Tyrosine Kinase Inhibitors. BMC Cancer, 14, Article No.: 910. https://doi.org/10.1186/1471-2407-14-910
|
[34]
|
Ullah, M.F., Bhat, S.H. and Abuduhier, F.M. (2016) Dietary Factors May Influence the Clinical Outcome of Chemotherapy in Cancer Multidrug Resistance. In: Ullah, M. and Ahmad, A., Eds., Critical Dietary Factors in Cancer Chemoprevention, Springer, Cham, 307-319. https://doi.org/10.1007/978-3-319-21461-0_15
|
[35]
|
Niki, K., Chara, P., Eleni, L., et al. (2013) Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide. PLoS ONE, 8, e74611. https://doi.org/10.1371/journal.pone.0074611
|
[36]
|
Fang, Z., Chen, W., Yuan, Z., et al. (2018) LncRNA-MALAT1 Contributes to the Cisplatin-Resistance of Lung Cancer by Upregulating MRP1 and MDR1 via STAT3 Activation. Biomedicine & Pharmacotherapy, 101, 536-542.
https://doi.org/10.1016/j.biopha.2018.02.130
|
[37]
|
Ji, G., Zhang, C., Guan, S., et al. (2018) Erlotinib for Progres-sive Brain and Leptomeningeal Metastases from HER2- Positive Breast Cancer after Treatment Failure with Trastuzumab and Lapatinib: Experience and Review of Literature. Clinical Breast Cancer, 18, e759-e765. https://doi.org/10.1016/j.clbc.2018.07.022
|
[38]
|
胡敏, 袁凯锋, 李晓明, 等. 伊马替尼、尼洛替尼和达沙替尼对慢性粒细胞白血病慢性期患者的临床疗效[J]. 中国临床药理学杂志, 2016(6): 511-513.
|
[39]
|
Martinez-Marti, A., Felip, E., Matito, J., et al. (2017) Dual MET and ERBB Inhibition Overcomes Intratumor Plasticity in Osimer-tinib-Resistant-Advanced Non-Small-Cell Lung Cancer (NSCLC). Annals of Oncology, 28, 2451-2457.
https://doi.org/10.1093/annonc/mdx396
|
[40]
|
Kim, C.W., Asai, D., Kang, J.H., et al. (2016) Reversal of Efflux of an Anticancer Drug in Human Drug-Resistant Breast Cancer Cells by Inhibition of Protein Kinase Cα (PKCα) Activity. Tumor Biology, 37, 1901-1908.
https://doi.org/10.1007/s13277-015-3963-4
|
[41]
|
Ji, N., Yang, Y., Cai, C.Y., et al. (2018) Selonsertib (GS-4997), an ASK1 Inhibitor, Antagonizes Multidrug Resistance in ABCB1 and ABCG2 Overexpressing Cancer Cells. Cancer Letters, 440-441, 82-93.
https://doi.org/10.1016/j.canlet.2018.10.007
|
[42]
|
Liu, W., Meng, Q., Sun, Y., et al. (2018) Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells. Cellular Physiology and Biochemistry, 51, 1616-1631. https://doi.org/10.1159/000495650
|
[43]
|
Takeda, N., Furuishi, M., Nishijima, Y., et al. (2018) Chiral Isoxazolidine-Mediated Stereoselective Umpolung α-Pheny- lation of Methyl Ketones. Organic & Biomolecular Chemistry, 16, 8940-8943. https://doi.org/10.1039/C8OB02480D
|
[44]
|
Yang, C.E., Lee, W.Y., Cheng, H.W., et al. (2019) The Antipsychotic Chlorpromazine Suppresses YAP Signaling, Stemness Properties, and Drug Resistance in Breast Cancer Cells. Chemico-Biological Interactions, 302, 28-35.
https://doi.org/10.1016/j.cbi.2019.01.033
|
[45]
|
Duan, Z., Zhang, J., Ye, S., Shen, J., et al. (2014) A-770041 Re-verses Paclitaxel and Doxorubicin Resistance in Osteosarcoma Cells. BMC Cancer, 14, Article No.: 681. https://doi.org/10.1186/1471-2407-14-681
|
[46]
|
Wang, K., Zhuang, Y., Liu, C., et al. (2012) Inhibition of c-Met Activation Sensitizes Osteosarcoma Cells to Cisplatin via Suppression of the PI3K-Akt Signaling. Archives of Bio-chemistry & Biophysics, 526, 38-43.
https://doi.org/10.1016/j.abb.2012.07.003
|
[47]
|
Ye, S.N., Zhang, J.M., Shen, J., et al. (2016) NVP-TAE684 Re-verses Multidrug Resistance (MDR) in Human Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function. British Journal of Pharmacology, 173, 613-626.
https://doi.org/10.1111/bph.13395
|
[48]
|
Jones, J., Choi, M.Y., Mato, A.R., et al. (2016) Venetoclax (VEN) Mon-otherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. Blood, 128, 637-637.
https://doi.org/10.1182/blood.V128.22.637.637
|
[49]
|
Wang, L., Yang, Z., Fu, J., et al. (2012) Ethaselen: A Potent Mammalian Thioredoxinreductase 1 Inhibitor and Novelorganoselenium Anticancer Agent. Free Radical Biology and Medicine, 52, 898-908.
https://doi.org/10.1016/j.freeradbiomed.2011.11.034
|
[50]
|
Xu, L., Lei, J., Jiang, D., et al. (2015) Reversal Effects of Raloxifene on Paclitaxel Resistance in 2 MDR Breast Cancer Cells. Cancer Biology & Therapy, 16, 1794-1801. https://doi.org/10.1080/15384047.2015.1095409
|
[51]
|
Di Pietro, A., Chiaradia-Delatorre, L.D., Gauthier, C., et al. (2014) Quinoxaline-Substituted Chalcones as New Inhibitors of Breast Cancer Resistance Protein ABCG2: Polyspeci-ficity at B-Ring Position. Drug Design Development & Therapy, 8, 609. https://doi.org/10.2147/DDDT.S56625
|
[52]
|
Bisi, A., Gobbi, S., Merolle, L., et al. (2015) Design, Synthesis and Biological Profile of New Inhibitors of Multidrug Resistance Associated Proteins Carrying a Polycyclic Scaffold. Eu-ropean Journal of Medicinal Chemistry, 92, 471-480.
https://doi.org/10.1016/j.ejmech.2015.01.004
|
[53]
|
Bisi, A., Cappadone, C., Rampa, A., et al. (2017) Coumarin Derivatives as Potential Antitumor Agents: Growth Inhibition, Apoptosis Induction and Multidrug Resistance Reverting Activity. European Journal of Medicinal Chemistry, 127, 577-585. https://doi.org/10.1016/j.ejmech.2017.01.020
|
[54]
|
Zhu, J., Wang, R., Lou, L., et al. (2016) Jatrophane Diterpenoids as Modulators of P-Glycoprotein-Dependent Multidrug Resistance (MDR): Advances of Structure-Activity Rela-tionships and Discovery of Promising MDR Reversal Agents. Journal of Medicinal Chemistry, 59, 6353-6369. https://doi.org/10.1021/acs.jmedchem.6b00605
|
[55]
|
Guo, C., Liu, F., Qi, J., et al. (2018) A Novel Synthetic Di-hydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells. Molecules, 23, 3264.
https://doi.org/10.3390/molecules23123264
|
[56]
|
Wang, J.Q., Li, J.Y. and Teng, Q.X. (2020) Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells. Cancers (Basel), 12, 466.
https://doi.org/10.3390/cancers12020466
|
[57]
|
Ranjbar, S., Khonkarn, R., Moreno, A., et al. (2019) 5-Oxo-Hexahydroquinoline Derivatives as Modulators of P-gp, MRP1 and BCRP Transporters to Overcome Multidrug Resistance in Cancer Cells. Toxicology and Applied Pharmacology, 362, 136-149. https://doi.org/10.1016/j.taap.2018.10.025
|